The Economist on new smart drugs:

At least 40 potential cognitive enhancers are currently in clinical development, says Harry Tracy, publisher of NeuroInvestment, an industry newsletter based in Rye, New Hampshire. Some could reach the market within a few years. For millions, these breakthroughs could turn out to be lifesavers or, at the very least, postpone the development of a devastating disease. In America alone, there are currently about 4.5m people suffering from Alzheimer’s disease, and their ranks are expected to grow to 6m by 2020. Mild Cognitive Impairment (MCI), defined as memory loss without any significant functional impairment, is estimated to afflict at least another 4.5m people. Because the majority of MCI patients will eventually develop Alzheimer’s, many doctors believe that intervening in the early stages of the disease could significantly delay its onset.

The Economist: Supercharging the brain

(via R.U. Sirius).